TIANYU PHARM: The active pharmaceutical ingredient of Irbesartan (Process II) has obtained the CEP certificate
I'm LongbridgeAI, I can summarize articles.TIANYU PHARM announced that the company has obtained the Certificate of Suitability to the European Pharmacopoeia (CEP certificate) for the active pharmaceutical ingredient Eprosartan (Process II) issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM). This drug is used for the treatment of primary hypertension and hypertension-related type 2 diabetic nephropathy. The company submitted the drug registration application to EDQM in December 2024 and successfully obtained the CEP certificate
According to the Zhitong Finance APP, TIANYU PHARM (300702.SZ) announced that the company has received the Certificate of Suitability for European Pharmacopoeia (CEP) issued by the European Directorate for the Quality of Medicines and HealthCare (EDQM) for the active pharmaceutical ingredient of Irbesartan (Process II).
Irbesartan is an antihypertensive medication used for the treatment of primary hypertension and for the treatment of hypertension in patients with type 2 diabetes and nephropathy. The company submitted the drug registration application for Irbesartan (Process II) to EDQM in December 2024 and obtained the CEP certificate